Tata India Pharma & Healthcare Fund Direct Growth
EquitySector - HealthcareVery High Risk
Direct
NAV (18-Jun-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹1,232 Cr
Expense Ratio
0.63%
ISIN
INF277K019A3
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
28 Dec 2015
About this fund
As of 18-Jun-25, it has a Net Asset Value (NAV) of ₹34.30, Assets Under Management (AUM) of 1231.67 Crores, and an expense ratio of 0.63%.
- Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.89% since inception.
- The fund's asset allocation comprises around 90.84% in equities, 0.00% in debts, and 9.16% in cash & cash equivalents.
- You can start investing in Tata India Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.71%
+14.51% (Cat Avg.)
3 Years
+27.20%
+25.57% (Cat Avg.)
5 Years
+23.11%
+21.51% (Cat Avg.)
Since Inception
+13.89%
— (Cat Avg.)
Portfolio Summaryas of 31st May 2025
| Equity | ₹1,118.8 Cr | 90.84% |
| Others | ₹112.87 Cr | 9.16% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹143.32 Cr | 11.64% |
| Cash / Net Current Asset | Cash - Collateral | ₹109.87 Cr | 8.92% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹76.55 Cr | 6.22% |
| Cipla Ltd | Equity | ₹71.82 Cr | 5.83% |
| Aurobindo Pharma Ltd | Equity | ₹70.6 Cr | 5.73% |
| Divi's Laboratories Ltd | Equity | ₹69.4 Cr | 5.63% |
| Fortis Healthcare Ltd | Equity | ₹60.4 Cr | 4.90% |
| Lupin Ltd | Equity | ₹59.37 Cr | 4.82% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹53.52 Cr | 4.35% |
| Wockhardt Ltd | Equity | ₹40.28 Cr | 3.27% |
| Dr Reddy's Laboratories Ltd | Equity | ₹38.98 Cr | 3.16% |
| Alkem Laboratories Ltd | Equity | ₹38.37 Cr | 3.11% |
| HealthCare Global Enterprises Ltd | Equity | ₹36.13 Cr | 2.93% |
| Ajanta Pharma Ltd | Equity | ₹23.79 Cr | 1.93% |
| Metropolis Healthcare Ltd | Equity | ₹22.96 Cr | 1.86% |
| Torrent Pharmaceuticals Ltd | Equity | ₹22.52 Cr | 1.83% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹22.41 Cr | 1.82% |
| Medi Assist Healthcare Services Ltd | Equity | ₹20.74 Cr | 1.68% |
| FDC Ltd | Equity | ₹20.68 Cr | 1.68% |
| Dr. Lal PathLabs Ltd | Equity | ₹20.4 Cr | 1.66% |
| Ipca Laboratories Ltd | Equity | ₹20.3 Cr | 1.65% |
| Indoco Remedies Ltd | Equity | ₹16.72 Cr | 1.36% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹15.58 Cr | 1.27% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹15.41 Cr | 1.25% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹14.71 Cr | 1.19% |
| Coromandel International Ltd | Equity | ₹13.74 Cr | 1.12% |
| Zydus Lifesciences Ltd | Equity | ₹12.77 Cr | 1.04% |
| Sanofi India Ltd | Equity | ₹11.87 Cr | 0.96% |
| Acutaas Chemicals Ltd | Equity | ₹11.76 Cr | 0.96% |
| Medplus Health Services Ltd | Equity | ₹11.48 Cr | 0.93% |
| Mankind Pharma Ltd | Equity | ₹10.23 Cr | 0.83% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹10.1 Cr | 0.82% |
| Procter & Gamble Health Ltd | Equity | ₹9.2 Cr | 0.75% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹8.11 Cr | 0.66% |
| Orchid Pharma Ltd | Equity | ₹7.23 Cr | 0.59% |
| Syngene International Ltd | Equity | ₹6.92 Cr | 0.56% |
| Inventurus Knowledge Solutions Ltd | Equity | ₹6.28 Cr | 0.51% |
| Deepak Nitrite Ltd | Equity | ₹3.63 Cr | 0.29% |
| A) Repo | Cash - Repurchase Agreement | ₹3 Cr | 0.24% |
| Laxmi Dental Ltd | Equity | ₹0.55 Cr | 0.04% |
Allocation By Market Cap (Equity)
Large Cap Stocks
29.13%
Mid Cap Stocks
32.34%
Small Cap Stocks
28.07%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹1,089.67 Cr | 88.47% |
| Basic Materials | ₹29.13 Cr | 2.37% |
Risk & Performance Ratios
Standard Deviation
This fund
16.18%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
1.04
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Fund Managers
Meeta Shetty
Since March 2021
Rajat Srivastava
Since September 2024
Additional Scheme Detailsas of 31st May 2025
ISIN | INF277K019A3 | Expense Ratio | 0.63% | Exit Load | No Charges | Fund Size | ₹1,232 Cr | Age | 9 years 5 months | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Pharma TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹321.02 Cr | - |
| Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹321.02 Cr | - |
| PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹108.88 Cr | - |
| PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹108.88 Cr | - |
| WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹331.66 Cr | 24.2% |
| WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹331.66 Cr | 26.4% |
| DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹10.25 Cr | 12.4% |
| Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹434.55 Cr | 13.7% |
| Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹434.55 Cr | 11.8% |
| HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹1704.87 Cr | 24.6% |
About the AMC
Total AUM
₹1,89,571 Cr
Address
Mafatlal Centre, 9th Floor, Mumbai, 400 021
Other Funds by Tata Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Tata India Pharma & Healthcare Fund Direct Growth?
What are the returns of Tata India Pharma & Healthcare Fund Direct Growth?
What is the portfolio composition of Tata India Pharma & Healthcare Fund Direct Growth?
Who manages the Tata India Pharma & Healthcare Fund Direct Growth?
- Meeta Shetty
- Rajat Srivastava
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.